The project has sequenced more than 1,700 individuals from across Asia to high coverage in order to bolster the representation of Asians in genomic research.
The Albert and Mary Lasker Foundation has announced the 2019 winners of its awards.
The FDA has granted accelerated approval to Rozlytrek as a treatment for adult and adolescent patients with NTRK fusion-positive cancers.
In the Phase I/IB study, only patients with NTRK or ROS1 fusions, or an ALK fusion or mutation responded to entrectinib, while patients without these tumor markers didn’t respond.
The company is also looking to expand the use of its FDA-approved ClonoSeq assay, which has US FDA approval for MRD detection in acute lymphocytic leukemia and multiple myeloma.
Adaptive will use its T-cell receptor screening platform to identify TCRs that can be used to target individual cancer patients' neoantigens.
New data on Kadcyla and Tecentriq will help doctors further refine precision medicine options for breast cancer patients with unmet needs.
In PNAS this week: germline variants influence tumor immune gene expression in two dozen cancer types, phylogenetic relationships of hemipteroid insects, and more.
During the meeting, researchers presented studies on combination immunotherapies and the efficacy of giving molecularly-informed treatments earlier in the disease continuum.
MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.
Gene editing could be an issue competitive sports need to address soon, four researchers from Arizona State University write at Slate.
A genetic alteration appears to increase heart failure risk among people of African descent, according to the Washington Post.
In his look back at the past decade, BuzzFeed News' Peter Aldhous writes that direct-to-consumer genetic testing has led to "Facebook for genes."
In Nature this week: genetic "clock" that can predict the lifespans of vertebrates, new assembler called wtdbg2, and more.